cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arbutus Biopharma Corporation
38 own
68 watching
Current Price
$3.64
$-0.09
(-2.41%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
425.95M
52-Week High
52-Week High
4.72000
52-Week Low
52-Week Low
1.70000
Average Volume
Average Volume
0.75M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization425.95M
icon52-Week High4.72000
icon52-Week Low1.70000
iconAverage Volume0.75M
iconDividend Yield--
iconP/E Ratio--
What does the Arbutus Biopharma Corporation do?
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
Read More
How much money does Arbutus Biopharma Corporation make?
News & Events about Arbutus Biopharma Corporation.
Globe Newswire
1 year ago
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (Arbutus or the Company), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to ...
TipRanks Financial Blog
1 year ago
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arbutus Biopharma (ABUS Research Report) and Evoge... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arbutus Biopharma (ABUS Research Report) and ...
PR Newswire
1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS PR Newswire NEW YORK, May 2, 2023 NEW YORK, May 2, 2023...
Globe Newswire
1 year ago
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post-AB-729 treatment AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in preclinical models WARMINSTER, Pa., April...
PR Newswire
1 year ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS PR Newswire NEW YORK, April 26, 2023 NEW YORK, April 26...
Frequently Asked Questions
Frequently Asked Questions
What is Arbutus Biopharma Corporation share price today?
plus_minus_icon
Can Indians buy Arbutus Biopharma Corporation shares?
plus_minus_icon
How can I buy Arbutus Biopharma Corporation shares from India?
plus_minus_icon
Can Fractional shares of Arbutus Biopharma Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Arbutus Biopharma Corporation stocks?
plus_minus_icon
What is today’s traded volume of Arbutus Biopharma Corporation?
plus_minus_icon
What is today’s market capitalisation of Arbutus Biopharma Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Arbutus Biopharma Corporation?
plus_minus_icon
What percentage is Arbutus Biopharma Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Arbutus Biopharma Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$3.64
$-0.09
(-2.41%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00